INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
Urinary tract infections (UTIs) are a common concern among patients with diabetes mellitus who are treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of hypoglycaemic medications. This systematic review and meta-analysis aimed to assess the incidence of UTIs in patients receiving SGLT2 inhibitors compared to other antidiabetic treatments or a placebo. A comprehensive literature search was conducted in major scientific databases, including PubMed, Embase, and Cochrane Library. Studies that reported the incidence of UTIs in adult patients with diabetes treated with SGLT2 inhibitors were included. The primary outcome measure was the incidence rate of UTIs, and secondary outcomes included the severity of UTIs and the association of UTIs with specific SGLT2 inhibitors. The pooled data revealed a higher overall incidence rate of UTIs in patients treated with SGLT2 inhibitors when compared to those on other antidiabetic therapies or placebo. Analysis based on specific SGLT2 inhibitors demonstrated varying degrees of UTI risk. Furthermore, the severity of UTIs in patients receiving SGLT2 inhibitors was found to be similar to those receiving alternative treatments or placebo. However, there was evidence of a higher frequency of genitourinary infections, particularly in females treated with SGLT2 inhibitors. The findings of this systematic review and meta-analysis highlight the increased risk of UTIs associated with SGLT2 inhibitor use in patients with diabetes. While SGLT2 inhibitors have shown significant benefits in glycaemic control, improving renal function and cardiovascular outcomes, physicians should be aware of this potential side effect and consider proper monitoring and preventive measures for patients at higher risk of developing UTIs. Future research may further explore the underlying mechanisms contributing to UTI risk with SGLT2 inhibitors and investigate strategies to alleviate this adverse effect.
"Incidence of asymptomatic urinary tract infections in patients with sodium Glucose Co- transporter (sglt2) inhibitors ", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 9, page no.c866-c869, September-2023, Available :http://www.ijnrd.org/papers/IJNRD2309297.pdf
Downloads:
000118759
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn